GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

UBT251

Company
The United Bio-Technology (Hengqin) Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
7 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

7 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for UBT251 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07134335

    UBT251 Injection Phase II Clinical Study (CKD)

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 180 participants Est. completion 2030-07-11 1 site Stand-alone
    Chronic kidney disease Other conditions: Obesity &Amp; Overweight
    View official trial listing →
  • Recruiting NCT NCT07145151

    A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 156 participants Est. completion 2027-08-31 1 site Stand-alone
    MASH
    View official trial listing →
  • Recruiting NCT NCT07395687

    A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

    Not yet reported Novo Nordisk A/S 333 participants Est. completion 2027-02-18 3 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07668388

    A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 300 participants Est. completion 2027-11-15 70 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07710729

    A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant

    Not yet reported Novo Nordisk A/S 40 participants Est. completion 2027-04-27 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07710768

    A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

    Not yet reported Novo Nordisk A/S 44 participants Est. completion 2027-04-07 1 site Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT07785934

    Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 48 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
    View official trial listing →
  • Completed NCT NCT07163624

    UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 211 participants Est. completion 2025-12-30 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07177469

    UBT251 Injection Phase II Study (Overweight or Obesity)

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 205 participants Est. completion 2025-11-19 1 site Stand-alone
    Other conditions: Obesity &Amp; Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07648225

    UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 600 participants Est. completion 2027-11-03 1 site Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07653477

    Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 956 participants Est. completion 2028-02-29 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07659574

    Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 360 participants Est. completion 2027-10-22 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07767942

    UBT251 Injection Phase Ⅲ Study (OSA-NPAP)

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 150 participants Est. completion 2028-10 Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Not yet recruiting NCT NCT07806851

    UBT251 Injection Phase Ⅲ Study (OSA-PAP)

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 150 participants Est. completion 2029-04 Stand-alone
    Obstructive sleep apnea Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.